سعر سومنياليتا 15مجم 60 قرص 2024

Sominaletta is an Egyptian phenobarbital (phenobarbitone) 15 mg oral tablet by Alexandria Co., pack of 60 tablets, classified by Egyptian directories as a barbiturate anti-epileptic.

• Treatment and control of all forms of epilepsy except absence seizures; use in febrile convulsions only in exceptional circumstances.Accord Healthcare UK (product database; MHRA-authorised SmPC)

• Reported effects include drowsiness, lethargy, memory and cognitive impairment, paradoxical excitement, confusion in the elderly, depression, ataxia, nystagmus, behavioural disturbances in children, hypotension, respiratory depression, megaloblastic anaemia, agranulocytosis, thrombocytopenia, hepatitis, cholestasis, allergic rashes, exfoliative dermatitis, SJS/TEN (very rare), antiepileptic hypersensitivity syndrome, osteomalacia and reduced bone mineral density with long-term use.International label, equivalent formulation · Accord Healthcare UK (product database; MHRA-authorised SmPC)

• Hypersensitivity to phenobarbital, other barbiturates or any tablet ingredient.International label, equivalent formulation · Accord Healthcare UK (product database; MHRA-authorised SmPC)
• Acute intermittent porphyria.International label, equivalent formulation · Accord Healthcare UK (product database; MHRA-authorised SmPC)
• Severe respiratory depression.International label, equivalent formulation · Accord Healthcare UK (product database; MHRA-authorised SmPC)

• Suicidal ideation and behaviour have been reported with antiepileptics; monitor patients and advise them to seek help if it occurs.International label, equivalent formulation · Accord Healthcare UK (product database; MHRA-authorised SmPC)
• Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported, mostly in the first weeks; stop treatment at the first signs and never restart.International label, equivalent formulation · Accord Healthcare UK (product database; MHRA-authorised SmPC)
• Avoid sudden withdrawal (severe withdrawal syndrome with rebound insomnia, anxiety, tremor, fits and delirium); prolonged use may cause alcohol-barbiturate type dependence; care in patients with drug abuse or alcoholism history.International label, equivalent formulation · Accord Healthcare UK (product database; MHRA-authorised SmPC)

• Alcohol and other CNS depressantsAdditive CNS depressant effect.Accord Healthcare UK (product database; MHRA-authorised SmPC)
• Valproate, phenytoin, oxcarbazepineMay increase phenobarbital plasma concentrations; monitor for hyperammonaemia with valproate.Accord Healthcare UK (product database; MHRA-authorised SmPC)
• Oral contraceptives (oestrogens/progestogens)Phenobarbital reduces contraceptive effect through enzyme induction.Accord Healthcare UK (product database; MHRA-authorised SmPC)

• Phenobarbital may cause foetal harm: in-utero exposure raises the risk of major malformations (about 6-7% vs 2-3% background), dose-dependently with no dose free of risk, and adverse neurodevelopmental effects; do not use in pregnancy unless the benefit outweighs the risks after considering alternatives, and then at the lowest effective dose. Women of childbearing potential should use highly effective contraception during and for 2 months after treatment.International label, equivalent formulation · Accord Healthcare UK (product database; MHRA-authorised SmPC)
• Phenobarbital is excreted into breast milk with a small risk of neonatal sedation; breastfeeding is not advisable.International label, equivalent formulation · Accord Healthcare UK (product database; MHRA-authorised SmPC)

• Phenobarbital (phenobarbitone): Probably prolongs the opening time of chloride channels in postsynaptic neuronal membranes, causing hyperpolarisation and impaired impulse propagation; also lowers intraneuronal sodium and inhibits calcium influx (UK SmPC section 5.1).